Literature DB >> 28368411

PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.

N Ueno1, N Nishimura1, S Ueno1, S Endo1, H Tatetsu1, S Hirata1, H Hata1, M Matsuoka1, H Mitsuya1, Y Okuno1.   

Abstract

We previously reported that PU.1 is downregulated in the majority of myeloma cell lines and primary myeloma cells of certain myeloma patients, and conditional expression of PU.1 in such myeloma cell lines induced cell cycle arrest and apoptosis. We found downregulation of IRF4 protein in the U266 myeloma cell line following induction of PU.1. Previous studies reported that knockdown of IRF4 in myeloma cell lines induces apoptosis, prompting us to further investigate the role of IRF4 downregulation in PU.1-induced cell cycle arrest and apoptosis in myeloma cells. PU.1 induced downregulation of IRF4 at the protein level, cell cycle arrest and apoptosis in six myeloma cell lines. Chromatin immunoprecipitation (ChIP) revealed that PU.1 directly binds to the IRF4 promoter, whereas a reporter assay showed that PU.1 may suppress IRF4 promoter activity. Stable expression of IRF4 in myeloma cells expressing PU.1 partially rescued the cells from apoptosis induced by PU.1. As it was reported that IRF4 directly binds to the IRF7 promoter and downregulates its expression in activated B cell-like subtype of diffuse large B cell lymphoma cells, we performed ChIP assays and found that IRF4 directly binds the IRF7 promoter in myeloma cells. It is known that IRF7 positively upregulates interferon-β (IFNβ) and induces apoptosis in many cell types. Binding of IRF4 to the IRF7 promoter decreased following PU.1 induction, accompanied by downregulation of IRF4 protein expression. Knockdown of IRF7 protected PU.1-expressing myeloma cells from apoptosis. Furthermore, IFNβ, which is a downstream target of IRF7, was upregulated in myeloma cells along with IRF7 after PU.1 induction. Finally, we evaluated the mRNA expression levels of PU.1, IRF4 and IRF7 in primary myeloma cells from patients and found that PU.1 and IRF7 were strongly downregulated in contrast to the high expression levels of IRF4. These data strongly suggest that PU.1-induced apoptosis in myeloma cells is associated with IRF4 downregulation and subsequent IRF7 upregulation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28368411     DOI: 10.1038/onc.2017.79

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

1.  ETS protein-dependent accessibility changes at the immunoglobulin mu heavy chain enhancer.

Authors:  B S Nikolajczyk; J A Sanchez; R Sen
Journal:  Immunity       Date:  1999-07       Impact factor: 31.745

2.  The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene.

Authors:  M J Klemsz; S R McKercher; A Celada; C Van Beveren; R A Maki
Journal:  Cell       Date:  1990-04-06       Impact factor: 41.582

Review 3.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

Review 4.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

5.  Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.

Authors:  Shinya Endo; Masayuki Amano; Nao Nishimura; Niina Ueno; Shikiko Ueno; Hiromichi Yuki; Shiho Fujiwara; Naoko Wada; Shinya Hirata; Hiroyuki Hata; Hiroaki Mitsuya; Yutaka Okuno
Journal:  Biochem Biophys Res Commun       Date:  2015-11-30       Impact factor: 3.575

Review 6.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

7.  PU.1 regulates positive regulatory domain I-binding factor 1/Blimp-1 transcription in lymphoma cells.

Authors:  Shruti Desai; Sophia C E Bolick; Michelle Maurin; Kenneth L Wright
Journal:  J Immunol       Date:  2009-10-14       Impact factor: 5.422

Review 8.  The interferon regulatory factor family in host defense: mechanism of action.

Authors:  Keiko Ozato; Prafullakumar Tailor; Toru Kubota
Journal:  J Biol Chem       Date:  2007-05-14       Impact factor: 5.157

9.  Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.

Authors:  Hiro Tatetsu; Shikiko Ueno; Hiroyuki Hata; Yasuhiro Yamada; Motohiro Takeya; Hiroaki Mitsuya; Daniel G Tenen; Yutaka Okuno
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

10.  A two-step, PU.1-dependent mechanism for developmentally regulated chromatin remodeling and transcription of the c-fms gene.

Authors:  Hanna Krysinska; Maarten Hoogenkamp; Richard Ingram; Nicola Wilson; Hiromi Tagoh; Peter Laslo; Harinder Singh; Constanze Bonifer
Journal:  Mol Cell Biol       Date:  2006-11-20       Impact factor: 4.272

View more
  7 in total

1.  Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma.

Authors:  Tiziana Bruno; Francesca De Nicola; Giacomo Corleone; Valeria Catena; Frauke Goeman; Matteo Pallocca; Cristina Sorino; Gianluca Bossi; Bruno Amadio; Giovanni Cigliana; Maria Rosaria Ricciardi; Maria Teresa Petrucci; Enrico Pierluigi Spugnini; Alfonso Baldi; Mario Cioce; Giancarlo Cortese; Elisabetta Mattei; Roberta Merola; Umberto Gianelli; Luca Baldini; Francesco Pisani; Svitlana Gumenyuk; Andrea Mengarelli; Katja Höpker; Thomas Benzing; Bruno Vincenzi; Aristide Floridi; Claudio Passananti; Giovanni Blandino; Simona Iezzi; Maurizio Fanciulli
Journal:  Blood Adv       Date:  2020-11-24

2.  Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia.

Authors:  Lukas Janker; Rupert L Mayer; Andrea Bileck; Dominique Kreutz; Johanna C Mader; Kirsten Utpatel; Daniel Heudobler; Hermine Agis; Christopher Gerner; Astrid Slany
Journal:  Mol Cell Proteomics       Date:  2019-02-21       Impact factor: 5.911

3.  Overexpression of long non-coding RNA WT1-AS or silencing of PIK3AP1 are inhibitory to cervical cancer progression.

Authors:  Wenjuan Tong; Huiming Zhang
Journal:  Cell Cycle       Date:  2021-11-28       Impact factor: 4.534

4.  Macrophage-targeted delivery of siRNA to silence Mecp2 gene expression attenuates pulmonary fibrosis.

Authors:  Yong Mou; Guo-Rao Wu; Qi Wang; Ting Pan; Lei Zhang; Yongjian Xu; Weining Xiong; Qing Zhou; Yi Wang
Journal:  Bioeng Transl Med       Date:  2022-01-18

5.  Down-regulation and clinical significance of miR-7-2-3p in papillary thyroid carcinoma with multiple detecting methods.

Authors:  Hua-Yu Wu; Yi Wei; Shang-Ling Pan
Journal:  IET Syst Biol       Date:  2019-10       Impact factor: 1.615

Review 6.  "Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease.

Authors:  Chinthalapally V Rao; Adam S Asch; Daniel J J Carr; Hiroshi Y Yamada
Journal:  Aging Cell       Date:  2020-01-25       Impact factor: 9.304

Review 7.  The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?

Authors:  Robert Ballotti; Yann Cheli; Corine Bertolotto
Journal:  Mol Cancer       Date:  2020-12-05       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.